| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 8153 |
| 1 | PEMBROLIZUMAB | 5933 |
| 2 | ENZALUTAMIDE | 4878 |
| 3 | EVEROLIMUS | 4027 |
| 4 | CARBOPLATIN | 3801 |
| 5 | IPILIMUMAB | 3125 |
| 6 | CAPECITABINE | 2894 |
| 7 | LETROZOLE | 2852 |
| 8 | FULVESTRANT | 2650 |
| 9 | PACLITAXEL | 2622 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AFATINIB | 1515 | 0.2633 |
| 1 | GEFITINIB | 1560 | 0.1917 |
| 2 | CERITINIB | 398 | 0.1838 |
| 3 | PRALATREXATE | 95 | 0.1789 |
| 4 | RUCAPARIB | 1111 | 0.1479 |
| 5 | RAMUCIRUMAB | 623 | 0.1389 |
| 6 | PEMBROLIZUMAB | 5933 | 0.1375 |
| 7 | OLAPARIB | 1320 | 0.1362 |
| 8 | STREPTOZOCIN | 20 | 0.1342 |
| 9 | FULVESTRANT | 2650 | 0.1258 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 14166 |
| 1 | Kinase Inhibitor [EPC] | 14081 |
| 2 | Platinum-based Drug [EPC] | 6344 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 5737 |
| 4 | Corticosteroid [EPC] | 5325 |
| 5 | Androgen Receptor Inhibitor [EPC] | 5219 |
| 6 | Microtubule Inhibitor [EPC] | 4423 |
| 7 | Aromatase Inhibitor [EPC] | 4329 |
| 8 | mTOR Inhibitor Immunosuppressant [EPC] | 4075 |
| 9 | Alkylating Drug [EPC] | 3231 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 623 | 0.1389 |
| 1 | Estrogen Receptor Antagonist [EPC] | 2650 | 0.1258 |
| 2 | Catecholamine Synthesis Inhibitor [EPC] | 5 | 0.1220 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 14166 | 0.1096 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 3125 | 0.1004 |
| 5 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 2179 | 0.0896 |
| 6 | Androgen Receptor Inhibitor [EPC] | 5219 | 0.0855 |
| 7 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 5 | 0.0769 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 668 | 0.0737 |
| 9 | Aromatase Inhibitor [EPC] | 4329 | 0.0533 |